Transformation of the National Breast Cancer Guideline Into Data-Driven Clinical Decision Trees

Mathijs P. Hendriks, MD¹; Xander A.A.M. Verbeek, PhD²; Thijs van Vegchel, MSc²; Maurice J.C. van der Sangen, MD, PhD³; Luc J.A. Strobbe, MD, PhD⁴; Jos W.S. Merkus, MD, PhD⁵; Harmien M. Zonderland, MD, PhD⁶; Carolien H. Smorenburg, MD, PhD⁷; Agnes Jager, MD, PhD⁸; and Sabine Siesling, PhD^{2,9}

PURPOSE The essence of guideline recommendations often is intertwined in large texts. This impedes clinical implementation and evaluation and delays timely modular revisions needed to deal with an ever-growing amount of knowledge and application of personalized medicine. The aim of this project was to model guideline recommendations as data-driven clinical decision trees (CDTs) that are clinically interpretable and suitable for implementation in decision support systems.

METHODS All recommendations of the Dutch national breast cancer guideline for nonmetastatic breast cancer were translated into CDTs. CDTs were constructed by nodes, branches, and leaves that represent data items (patient and tumor characteristics [eg, T stage]), data item values (eg, T2 or less), and recommendations (eg, chemotherapy), respectively. For all data items, source of origin was identified (eg, pathology), and where applicable, data item values were defined on the basis of existing classification and coding systems (eg, TNM, Breast Imaging Reporting and Data System, Systematized Nomenclature of Medicine). All unique routes through all CDTs were counted to measure the degree of data-based personalization of recommendations.

RESULTS In total, 60 CDTs were necessary to cover the whole guideline and were driven by 114 data items. Data items originated from pathology (49%), radiology (27%), clinical (12%), and multidisciplinary team (12%) reports. Of all data items, 101 (89%) could be classified by existing classification and coding systems. All 60 CDTs could be integrated in an interactive decision support app that contained 376 unique patient subpopulations.

CONCLUSION By defining data items unambiguously and unequivocally and coding them to an international coding system, it was possible to present a complex guideline as systematically constructed modular data-driven CDTs that are clinically interpretable and accessible in a decision support app.

Clin Cancer Inform. © 2019 by American Society of Clinical Oncology

INTRODUCTION

The National Academy of Medicine defines clinical practice guidelines as “statements that include recommendations, intended to optimize patient care, that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options.”^{1(p4)} It has been shown that their implementation reduces unwanted variability in clinical practice and improves outcome, therefore improving the quality of care.²

Quick and continuous revision and subsequent implementation and evaluation of guidelines in clinical practice are essential but challenging for several reasons.³ First, guideline development is time consuming and modular revision (meant to accelerate the revision process) cumbersome because modules often are intertwined in the entire guideline text. Second, as cancer treatment is getting more personalized and

based on (biomarker) data, guideline recommendations need to be defined for ever-smaller and more-specific patient populations, which makes them more complex. Finally, routine, explicit guideline utilization for each patient is cumbersome because of ambiguity in guideline texts attributable to the use of equivocal terms.

Methods for transforming guidelines into computer-interpretable formats are well studied and have been successfully used for relatively simple guidelines, such as medication alerts to warn for potential contraindications.⁴⁻⁶ However, these methods often are aimed at how to describe guidelines in formal computer languages and not as much at the actual translation of free-text guidelines into such formats. Moreover, such descriptions are difficult to grasp and interpret by physicians involved in guideline committees. Therefore, the application of such an approach to complex multidisciplinary (oncology) guidelines has remained challenging. Occasionally, guidelines, such

ASSOCIATED CONTENT

Appendix

Data Supplement

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on April 4, 2019 and published at ascopubs.org/journal/cci on May 29, 2019; DOI <https://doi.org/10.1200/CCI.18.00150>

CONTEXT SUMMARY

Key Objective

To develop a scalable method for representing textual guideline recommendations as systematically designed, modular, data-driven clinical decision trees (CDTs) and to apply this method on a complex guideline. We tested this method using the Dutch national breast cancer guideline.

Knowledge Generated

The rules that comprise CDTs can be systematically derived from guideline recommendations. At each point in the care path, the CDT describes the most appropriate new interventions on the basis of the accumulating patient data available up to that point. We demonstrate the feasibility of applying the CDT method on a complex guideline. Data items that comprise the CDT were defined unequivocally and unambiguously on the basis of international classification and coding systems. In this way, interoperability with electronic health records and implementation of CDTs in decision support systems can be facilitated.

Relevance

The modular character of CDTs could provide a means for quick and clear implementation and accessibility of dynamic guidelines. Moreover, fast-growing knowledge could be taken into account more rapidly and easily by modular updating of CDTs, which supports implementation of data-driven personalized health care.

as those of the National Comprehensive Cancer Network (NCCN), are presented in widely used, compact flowcharts. However, these flowcharts are not fully data modulated, and a strict relationship between all possible (combinations of) patient/disease characteristics and guideline recommendations is not always present.

To anticipate these challenges and complement the NCCN flowcharts, we hypothesized that the transformation of guideline text into data-driven clinical decision trees (CDTs) can facilitate the continuous cycle of guideline development, implementation, evaluation, revision, and maintenance.⁷ We therefore set up a project that transformed the Dutch national breast cancer guideline into CDTs.⁸ Our aim was to model systematically all national breast cancer guideline recommendations for non-metastatic breast cancer as data-driven CDTs on the basis of existing classification systems. When we succeed, we will try to develop an app that clinicians can use directly in daily practice, that complies with prerequisites for integration into the electronic health record (EHR), and that facilitates continuous learning from real-time data.

METHODS

To represent text-based guideline recommendations in CDTs, we used a repetitive data collection approach for each step in a nominal patient-centric care pathway (Fig 1). Our method is based on a generic model for patient disease state that regresses, remains stable, or progresses either spontaneously or as a result of care interventions. During care, data that describe the disease state accumulate. The care pathway is decomposed into interventions for measuring the disease state (eg, diagnoses) that result in new data, which add to prior knowledge, and into interventions that influence the disease state. At each point, the CDTs describe the most appropriate new intervention on the

basis of data available up to that point. The rules that comprise the CDT are derived from guideline recommendations. All CDTs can be used independently from one another (eg, a CDT for postoperative treatment can be used independently from a CDT for preoperative treatment and its outcome). By connecting CDTs head to tail, the actual care pathway can be reconstructed. The model is scalable across diseases because at no point are assumptions made on care process or type of data.

Guideline text recommendations were mapped according to this approach and subsequently for each step modeled into data-driven CDTs. The method was applied to the 2012 version of the Dutch national breast cancer guideline. CDTs were developed together with researchers of the Netherlands Comprehensive Cancer Organization assisted by a multidisciplinary panel of breast cancer specialists (including surgeons, medical and radiation oncologists, radiologists, and pathologists) and supervised by the members of the Dutch national guideline working group to ensure accuracy and clinical interpretability.

CDTs

CDTs consist of nodes, branches, and leaves. For modeling and visualization of a CDT, the following concepts were used: The trunk of the tree represents the step in the care pathway to which the recommendation applies (eg, postoperative treatment tree). The nodes represent patient or tumor characteristics (eg, T stage) formulated as data items (eg, T2 or less). Data items are derived from medical history, physical examination, or diagnostic tests and can be independent (eg, tumor diameter) or dependent (eg, a data item that is classified as a category on the basis of another data item, such as T stage derived from tumor diameter). The branches represent cutoff points. The leaves represent patient-specific recommendations (eg,

FIG 1. Conceptual and simplified reflection of the breast cancer care pathway and related clinical decision trees (CDTs). See the Methods section for a detailed description. A, age; CT, computed tomography; D, tumor diameter; DCIS, ductal carcinoma in situ; G, tumor grade; M, tumor morphology; MDT, multidisciplinary team; MRI, magnetic resonance imaging; R, residual tumor; T, tumor stage; US, ultrasound.

treatment recommendations, advice to perform a diagnostic test). It is optional to present the level of evidence that underlies a specific recommendation.

In each CDT, the patient or population, intervention, comparison, and outcome (PICO) system is represented. Leaves represent recommended interventions, and the collection of nodes and cutoff points that lead to a leaf represent the patient or population to whom the recommendation applies. Information such as background literature, studies that compare outcomes of various diagnostic or treatment strategies, and level of evidence is provided as meta-information that underlies the leaves (recommendations).⁹ This PICO strategy is supported by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to judge and grade the quality of scientific publications that indicate levels of evidence.^{10,11} CDTs were constructed manually by systematically applying this approach to translate each guideline recommendation. All CDTs were checked and formally approved by the Dutch national guideline working group.

Implementation in Decision Support Systems and Interoperability

To establish the source of data that drives guideline recommendations, we identified the source record (eg, pathology or radiology report) for each data item. Data items analyzed included source of data origin (eg, pathology, radiology) and relation to classification systems (eg, TNM, Breast Imaging Reporting and Data System [BIRADS]).

To quantify linguistic unity (or lack thereof), we kept track of the number of different terms used in the free-text guidelines for each data item. For the purpose of linguistic unity, data items in nodes and interventions in leaves were described as much as possible using the most accepted, to our knowledge, international classification and coding systems (eg, TNM; BIRADS; International Classification of Diseases for Oncology, Third Edition; Systematized Nomenclature of Medicine Clinical Terms [SNOMED CT (SNOMED International 2018 version 1.37.3)]). Prerequisites for implementing CDTs in decision support systems and interoperability with EHRs are the systematic construction of CDTs as described herein and the unequivocal and unambiguous definition of data items on the basis of internationally acknowledged classification and coding systems. The reason for using international classification or coding systems is interoperability. Technically, our method allows for associating a single data item with codes from one or more coding or classification systems (one-to-many relationship) that express the same (eg, as can be the case in SNOMED CT and Logical Observation Identifiers Names and Codes). In this way, interoperability challenges faced during implementation can be solved pragmatically, depending on the choices made in source systems such as an EHR. Furthermore, the choice of the appropriate classification systems is included, in most cases, in the guideline itself (eg, TNM for cancer staging, BIRADS for radiology outcomes, New York Heart Association classification for heart failure, Eastern Cooperative Oncology Group or WHO for performance score).

Personalization

To express the complexity and degree to which guideline recommendations are personalized, all unique patient routes through all CDTs, which reflect patient subpopulations, were counted.

Decision Support

The CDTs were developed using Gaston (Medical Decision Support Systems BV, Eindhoven, the Netherlands).¹² CDTs were created by simple drag-and-drop actions, using the data items as building blocks. Data items themselves were defined and coded (eg, SNOMED CT) in ART-DECOR (Advanced Tooling Requirements-Data Elements Codes, Object Identifiers and Rules), which is an international open source tool used by the Dutch National Institute for Information and Communication Technology (<https://www.nictiz.nl/standaardisatie/art-decor>) for development, maintenance, and publication of information standards for interoperability. Accordingly, the CDTs are interoperable per design, and a direct relation between information derived from different sources (eg, pathology or radiology reports) is modeled in such a way to enable (digital) information exchange and interoperability among the various actors in the care pathway.

CDTs were implemented in an interactive decision support application, Oncoguide (www.oncoguide.nl), which is also available for tablet computers. The application is designed to be used as a stand-alone app for manual data entry and to connect to EHRs for automatic electronic data exchange. For the latter, Oncoguide is accessible through RESTful Web Services (an application programming interface) and thereby follows the latest development on the Fast Health Interoperability Resources infrastructure of the international HL7 community (<http://www.hl7.org/Special/committees/fiwig/index.cfm>).

RESULTS

CDTs

We translated the recommendations of the Dutch national breast cancer guideline (199 pages, A4 text format, 9,920 line numbers, 100,564 words, 13 chapters, and seven appendices) into 60 CDTs driven by 98 independent and 16 dependent data items. Figure 2 shows an example of a CDT. Table 1 lists a classification of data items with respect to their record source. Most objective data items originated from pathology reports (56 of 114; 49%), followed by radiology reports (30 of 114; 27%), clinical patient characteristics (14 of 114; 12%), and multidisciplinary team interpretation/validation (14 of 114; 12%). A list of all data items can be found in Appendix Table A1.

Implementation in Decision Support and Interoperability

Of all data items, 89% could be classified by existing classification and/or coding systems. On the basis of existing classification systems only, 75 (65%) of 114 data items were classified (66 to TNM, eight to BIRADS, and one

to Response Evaluation Criteria in Solid Tumors [RECIST]). On the basis of the coding system SNOMED CT, only 90 (79%) of 114 data items could be classified. Ten data items could be qualified as too ambiguous to quantify (eg, size of ductal carcinoma in situ compared with breast volume; Appendix Table A1).

Twenty-two of 60 CDTs concerned recommendations for diagnostics, whereas 33 of 60 CDTs involved treatment recommendations. Five (8%) of 60 CDTs lacked recommendations because guideline recommendations were not available (eg, evaluation of surgical margin after treatment, recurrent disease).

By constructing CDTs systematically, all possible outcome values of each data item should lead to a recommendation. Four situations were identified for which the guideline represents no recommendation (as yet). For example, when a left ventricular ejection fraction of less than 50% is found in human epidermal growth factor receptor 2–positive breast cancer, the guideline lacks recommendations. As an example of ambiguity of data items within the guideline, Table 2 lists the many definitions of the data item margin status used in different classification systems.

Personalization

In each CDT, there were one or more possible routes to reach one of the available recommendations, each of them defining a specific patient subpopulation. The total possible number of unique patient routes through all CDTs that led to one or more recommendations was 376 (see Appendix Fig A1). The mean number of possible patient routes per CDT was equal for CDTs that lead to treatment recommendations (6.4; median, four; range, one to 24) compared with CDTs that lead to diagnostic recommendations (6.3; median, three; range, one to 18).

Decision Support

All CDTs were successfully integrated in the interactive decision support app Oncoguide and are accessible free of charge (see Methods section). In the app, patient data are projected on the CDTs and show the path to the automatically generated patient-specific recommendation.

DISCUSSION

We show that it is feasible to transform a complex text-based guideline, such as the Dutch national breast cancer guideline, into data-driven CDTs. Although the concept of decision trees is not new, the clinical application of data-driven, moderated CDTs on a complex medical multidisciplinary guideline in such a way that they are both clinically interpretable and suitable for implementation in decision support systems has not been described earlier.¹⁴ By defining the data items needed for the CDTs, it was mostly possible to adhere to international classification and coding standards, although 21% of the data items needed to cover the complete guideline was not available in SNOMED CT. Although this does not limit the possibility to model

FIG 2. Example of a clinical decision tree (CDT). (A) The top rectangle reflects the trunk of the CDT postoperative treatment. The rhombuses reflect the nodes and represent the data items. The branches define the cutoff values, which lead to additional nodes (rhombuses) or guideline recommendations (bottom rectangles; a delineated recommendation [rectangle with a curly bottom] means referral to another CDT, such as locoregional treatment after breast-conserving surgery[BCS]). (B) Note the double-delineated rhombus margin status, which can be unfolded to define the value of margin status. In contrast to other countries, the Dutch national breast cancer guideline does not recommend re-excision for focally positive margins after BCS in invasive tumor and recommends whole-breast irradiation, including boost.¹³

TABLE 1. Sources of 114 Data Items That Appear in All Clinical Decision Trees

Data Item Classification	Pathology	Radiology	Clinical	MDT	Total
Subjective	0	3	1	7	11
Objective	56	27	13	7	103
No. (%)	56 (49)	30 (27)	14 (12)	14 (12)	114 (100)

NOTE. Data items can be classified objectively (eg, tumor diameter) or subjectively (eg, size of ductal carcinoma in situ compared with breast volume). Clinical refers to data items that are classified by clinical judgment (eg, inflammatory breast), and MDT reflects data items classified by the MDT (eg, discrepancy between clinical findings and imaging). A full list of all data items can be found in Appendix Table A1.

Abbreviation: MDT, multidisciplinary team.

recommendations as CDTs, closing this gap is important because different international guidelines (NCCN, European Society of Medical Oncology) can only give complementary recommendations if there is consensus about the definitions of all data items that determine diagnostic or treatment recommendations. For items currently not covered in SNOMED CT, we have put forward change requests for their inclusion at SNOMED International.

Because of the vagueness of recommendations, guidelines are sometimes criticized for not being helpful in practice.^{15,16} Different definitions of certain data values (Table 2) were encountered in the different chapters of the guideline, which automatically show up while designing CDTs. In this way, the CDT method is also a quality control

instrument because it needs consequent and equivocal definitions. In contrast with text-based guidelines, our method can help the guideline updating process because it is based on compact guideline modules, and one can focus on the modules that need revision.

Clinical decision making is more and more personalized, and this is reflected in 376 unique subpopulations already described in the Dutch national breast cancer guideline. It is likely that this number will increase substantially because available pathology and genomic data will affect guideline recommendations soon. Moreover, in 2016, ASCO recommended the integration of higher-quality genomic data into clinical practice.¹⁷ These data can be modularly incorporated in CDTs.

In contrast to NCCN guidelines and flowcharts, our method of systematically constructed CDTs is fully data driven and delivers unambiguously and unequivocally defined and coded data items that relate all possible (combinations of) patient/disease characteristics to subpopulation-specific guideline recommendations. To our knowledge, only a few guideline-based clinical decision support systems have been routinely used for breast cancer management in the hospital setting.¹⁸⁻²¹ However, these local initiatives use decision rules and do not cover full national guidelines.

In 2012, ASCO started with the development of Cancer-LinQ, a rapid learning system to improve the quality and efficiency of cancer care by generating new knowledge on

TABLE 2. Definitions of Margin Status Used in the Dutch National Breast Cancer Guideline and Other National and International Scientific Authoritative Sources

Authority	Definition
Dutch breast cancer guideline 2012	Free, focal not free,* more than focal not free Tumor-positive margin status v tumor-negative margin status Radical margin status v not radical Tumor growth into a surgical margin
PALGA	Free Focal not free (tumor margin $\leq$ 4 mm) More than focal not free
TNM atlas (resection margin)	R0: no residual tumor R1: microscopic residual tumor R2: macroscopic residual tumor
NBCA	Radical Focal not radical More than focal not radical Unknown/not able to be judged
Dutch cancer registry	Radical or not apparent and DCIS radical or not apparent Radical or not apparent and DCIS focal not radical Radical or not apparent and DCIS not radical Focal not radical and DCIS radical or not apparent Focal not radical and DCIS focal not radical Focal not radical and DCIS not radical Not radical and not important Unclear mention of radicality of invasive and/or DCIS component

Abbreviations: DCIS, ductal carcinoma in situ; NBCA, NABON Breast Cancer Audit; PALGA, Dutch nationwide network and registry of histo- and cytopathology.

*Tumor reaching an inked surface in a limited surface ($\leq$ 4 mm).

FIG 3. Screenshot that shows a part of the clinical decision tree (CDT) for indication genomic testing in Oncoguide (translated into English). The green path through the CDT highlights the data provided in the data panel on the left side projected onto the CDT, which in this case leads to the recommendation that genomic testing is indicated. The full tree (in Dutch) is also accessible in an interactive format through <https://oncoguide.nl/#/projects/7/guideline/17/tree/153/10494>. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; neg, negative; pos, positive.

the basis of aggregated real-world patient data extracted from EHRs.^{22,23} Decision support systems, such as the Oncoguide app, can help to bring this goal a step closer because this tool is able to register patient subpopulation treatment choices and reasons for guideline deviations. The application of Oncoguide for decision support has been evaluated in comparison with Watson (IBM, Armonk, NY) on the basis of synthetic patient cases.²⁴ However, additional research is needed to evaluate the value of guidelines-based decision support in daily clinical practice.

All CDTs together cover the whole care pathway for non-metastatic breast cancer and follow all diagnostic and therapeutic options on the basis of the guideline. From our systematic method of constructing CDTs emerged five CDTs that lack recommendations, which pinpoints guideline gaps or, in other words, patient subpopulations that are not fully discussed in the guideline. These gaps can be addressed in future guideline updates.

Protocols, standardized reporting, and decision trees are sometimes put aside as cookbook medicine that ignores the fundamentally uncertain nature of medicine.²⁵ However, the method described in this article does not reduce the level of evidence and secondary strength of recommendations in CDTs where evidence is weak or lacking. Although CDTs lack large text documents, no information is lost. Classification of recommendations by international grading systems, such as GRADE, is maintained.¹¹ Likewise, as with text-based guidelines, it is up to the physicians to adhere to or deviate from the recommendations mentioned in the CDTs.⁷

A strength of this study is that we tested the method of CDTs by applying it to a highly complex multidisciplinary guideline while strictly adhering to international classification and coding systems. Moreover, our method is generalizable for guidelines in other disease areas where recommendations are based on the PICO system. The method already has been applied successfully to guidelines

for other types of cancer, including to NCCN guidelines and Dutch nursing guidelines for pain management and wound care (all accessible online in Oncoguide).²⁶ Furthermore, because no assumptions are needed for how the care process is organized, this model is scalable toward the future when more data become available. Similarly, this model is scalable across diseases, provided that CDTs are constructed systematically as described in the Methods section.

In this study, we tested the feasibility of modeling a complex textual guideline into systematically designed, modular, data-driven CDTs as the basis for a decision support system that can be used as a stand-alone application and has the ability to connect to EHRs through modern Web interfaces using international standards for electronic patient data exchange. Data on the practical application of CDTs in clinical practice is needed, however. Therefore, we are currently working with Dutch hospitals and EHR vendors to implement and evaluate the application of CDT-based decision support in routine clinical practice. Application of CDTs in practice and compliance of EHR documentation with the associated information standard offer to facilitate decision making and continuously evaluate and improve guidelines by comparison with real-live data. In addition to guideline recommendations, other types of knowledge can be represented as CDTs, such as clinical trial or genomic testing (MammaPrint [Agendia, Amsterdam, the Netherlands] and Oncotype DX [Genomic Health, Redwood City, CA]) indications. As an example of the latter, [Figure 3](#)

shows a CDT with recommendations for genomic testing in the Oncoguide application.

In conclusion, it is possible to present the complex Dutch national breast cancer guideline as clinically interpretable, modular, data-driven CDTs by using a set of 114 data items, 89% of which are defined by existing international classification and coding systems. The modular character of CDTs could provide a means for quick and clear implementation and accessibility of dynamic guidelines. Moreover, fast-growing knowledge could more rapidly and easily be taken into account by modularly updating CDTs, which supports implementation of data-driven personalized health care.

To demonstrate the potential application of CDTs as decision support, all CDTs were successfully implemented in an interactive decision support app, Oncoguide. Oncoguide provides a framework to register unique patient subpopulations and has the potency to report on physician, and potentially patient, motivation for guideline adherence or nonadherence in daily practice, which facilitates collaborative learning and improves the quality of care.²⁷ Connection of Oncoguide to the EHR will be an essential next step to enable routine use of decision support in daily practice. The unequivocal and unambiguous definition of data items is an essential prerequisite for implementation of CDTs in decision support systems, and reaching consensus internationally on these definitions is a challenge for all national and international guideline working groups.

AFFILIATIONS

¹Northwest Clinics, Alkmaar, the Netherlands

²Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands

³Catharina Hospital, Eindhoven, the Netherlands

⁴Canisius Wilhelmina Hospital, Nijmegen, the Netherlands

⁵Haga Teaching Hospital, The Hague, the Netherlands

⁶University of Amsterdam, the Netherlands

⁷Netherlands Cancer Institute, Amsterdam, the Netherlands

⁸Erasmus MC Cancer Institute, Rotterdam, the Netherlands

⁹University of Twente, Enschede, the Netherlands

CORRESPONDING AUTHOR

Mathijs P. Hendriks, MD, Department of Medical Oncology, Northwest Clinics, Wilhelminalaan 12, 1815JD Alkmaar, the Netherlands; e-mail: m.p.hendriks@nwz.nl.

EQUAL CONTRIBUTION

A.J. and S.S. contributed equally.

PRIOR PRESENTATION

Presented at the National Comprehensive Cancer Network 23rd Annual Conference, Orlando, FL, March 22-24, 2018.

AUTHOR CONTRIBUTIONS

Conception and design: Mathijs P. Hendriks, Xander A.A.M. Verbeek, Thijs van Vegchel, Maurice J.C. van der Sangen, Luc J.A. Strobbe, Jos W.S. Merkus, Sabine Siesling

Administrative support: Thijs van Vegchel

Provision of study material or patients: All authors

Collection and assembly of data: Mathijs P. Hendriks, Xander A.A.M. Verbeek, Thijs van Vegchel

Data analysis and interpretation: All authors

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/cci/author-center.

Mathijs P. Hendriks

Consulting or Advisory Role: MSD

Carolien H. Smorenburg

Travel, Accommodations, Expenses: Roche

No other potential conflicts of interest were reported.

REFERENCES

1. Graham R, Mancher M, Miller Wolman D, et al (eds): Clinical Practice Guidelines We Can Trust. Washington, DC, National Academies Press, 2011
2. Panella M, Marchisio S, Di Stanislao F: Reducing clinical variations with clinical pathways: Do pathways work? *Int J Qual Health Care* 15:509-521, 2003
3. Martínez García L, Sanabria AJ, García Alvarez E, et al: The validity of recommendations from clinical guidelines: A survival analysis. *CMAJ* 186:1211-1219, 2014
4. De Clercq P, Kaiser K, Hasman A: Computer-interpretable guideline formalisms. *Stud Health Technol Inform* 139:22-43, 2008
5. Peleg M: Computer-interpretable clinical guidelines: A methodological review. *J Biomed Inform* 46:744-763, 2013
6. Robertson J, Walkom E, Pearson SA, et al: The impact of pharmacy computerised clinical decision support on prescribing, clinical and patient outcomes: A systematic review of the literature. *Int J Pharm Pract* 18:69-87, 2010
7. Quality of Care Directorate: Directive for Guidelines: 20 Criteria for Developing and Implementing a Clinical Guideline [in Dutch]. The Hague, the Netherlands, Quality of Care Directorate, 2012
8. NABON: Breast Cancer: Dutch Guideline, Version 2.0, 2012. <https://www.oncoline.nl/uploaded/docs/mammacarcinoom/Dutch%20Breast%20Cancer%20Guideline%202012.pdf>
9. Huang X, Lin J, Demner-Fushman D: Evaluation of PICO as a knowledge representation for clinical questions. *AMIA Annu Symp Proc* 359-363, 2006
10. Burgers JS, van Everdingen JJ: Evidence-based guideline development in the Netherlands: The EBRO platform [in Dutch]. *Ned Tijdschr Geneesk* 148:2057-2059, 2004
11. Hultcrantz M, Rind D, Akl EA, et al: The GRADE Working Group clarifies the construct of certainty of evidence. *J Clin Epidemiol* 87:4-13, 2017
12. de Clercq PA, Hasman A, Blom JA, et al: Design and implementation of a framework to support the development of clinical guidelines. *Int J Med Inform* 64:285-318, 2001
13. Vos EL, Siesling S, Baaijens MHA, et al: Omitting re-excision for focally positive margins after breast-conserving surgery does not impair disease-free and overall survival. *Breast Cancer Res Treat* 164:157-167, 2017
14. Shiffman RN, Greenes RA: Improving clinical guidelines with logic and decision-table techniques: Application to hepatitis immunization recommendations. *Med Decis Making* 14:245-254, 1994
15. Merkow RP, Korenstein D, Yeahia R, et al: Quality of cancer surveillance clinical practice guidelines: Specificity and consistency of recommendations. *JAMA Intern Med* 177:701-709, 2017
16. Codish S, Shiffman RN: A model of ambiguity and vagueness in clinical practice guideline recommendations. *AMIA Annu Symp Proc* 146-150, 2005
17. Hughes KS, Ambinder EP, Hess GP, et al: Identifying health information technology needs of oncologists to facilitate the adoption of genomic medicine: Recommendations from the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop. *J Clin Oncol* 35:3153-3159, 2017
18. Patkar V, Acosta D, Davidson T, et al: Using computerised decision support to improve compliance of cancer multidisciplinary meetings with evidence-based guidance. *BMJ Open* 2:e000439, 2012
19. Eccher C, Seyfang A, Ferro A: Implementation and evaluation of an Asbru-based decision support system for adjuvant treatment in breast cancer. *Comput Methods Programs Biomed* 117:308-321, 2014
20. Bouaud J, Spano JP, Lefranc JP, et al: Physicians' attitudes towards the advice of a guideline-based decision support system: A case study with OncoDoc2 in the management of breast cancer patients. *Stud Health Technol Inform* 216:264-269, 2015
21. Séroussi B, Guézennec G, Lamy JB, et al: Reconciliation of multiple guidelines for decision support: A case study on the multidisciplinary management of breast cancer within the DESIREE project. *AMIA Annu Symp Proc* 2017:1527-1536, 2018
22. Sledge GW Jr, Miller RS, Hauser R: CancerLinQ and the future of cancer care. *Am Soc Clin Oncol Educ Book* 33:430-434, 2013
23. Schilsky RL, Michels DL, Kearbey AH, et al: Building a rapid learning health care system for oncology: The regulatory framework of CancerLinQ. *J Clin Oncol* 32:2373-2379, 2014
24. Keikes L, Medlock S, van de Berg DJ, et al: The first steps in the evaluation of a "black-box" decision support tool: A protocol and feasibility study for the evaluation of Watson for oncology. *J Clin Transl Res* 3:411-423, 2018 (suppl 3)
25. Morris AH: Computerized protocols and bedside decision support. *Crit Care Clin* 15:523-545, 1999
26. Ebben K, Lamb P, van der Werf J, et al: A Method for structured comparison of oncologic clinical practice guidelines. National Comprehensive Cancer Network Annual Conference, Orlando, FL, March 22-24, 2018
27. Abernethy AP, Etheredge LM, Ganz PA, et al: Rapid-learning system for cancer care. *J Clin Oncol* 28:4268-4274, 2010

APPENDIX

FIG A1. A unique patient route within a clinical decision tree that is based on the Dutch breast cancer guideline 2012. ALND, axillary lymph node dissection; BCS, breast-conserving surgery; LCIS, lobular carcinoma in situ; mi, micrometastasis; MDT, multidisciplinary team; paget, Paget's disease; sn, sentinel node; SNP, sentinel node procedure.

TABLE A1. All 114 Unique Data Items

Data Item	SNOMED CT Description	Ambiguity in Data Item Present?	Data Source
Discrepancy between clinical findings and imaging	Discrepancy (finding)	No	MDT
Systemic treatment administered	Chemotherapy, endocrine therapy	No	MDT
Size DCIS compared with breast volume	NA	Yes	MDT
Cycle systemic therapy ended	Postchemotherapy	No	MDT
Treatment line endocrine therapy	Endocrine therapy	No	MDT
Representative cytology specimen	NA	Yes	MDT
Representative histology specimen	NA	Yes	MDT
Lymph node surgery	Lymph node operation	No	MDT
Breast tumor surgery	Breast operation	No	MDT
History of regional radiotherapy	Radiotherapy to breast	No	MDT
Resectability relapse	NA	Yes	MDT
History of chest wall radiotherapy	Radiotherapy to thorax	No	MDT
Time expired since incidence date	NA	No	MDT
Extension in adjacent structures	Tumor extension	No	MDT
Breastfeeding	Breast feeding	No	Clinical
Fixed axillary lymph nodes	N2 metastases to ipsilateral axillary lymph node(s) fixed to one another or to other structures	No	Clinical
Sex	Sex	No	Clinical
Inflammatory breast	Inflammatory breast disease	No	Clinical
Clinically positive axillary lymph nodes	Axillary lymphadenopathy	No	Clinical
Clinically positive infraclavicular lymph nodes	Infraclavicular lymphadenopathy	No	Clinical
Clinically positive parasternal lymph nodes	Parasternal lymphadenopathy	No	Clinical
Clinically positive supraclavicular lymph nodes	Supraclavicular lymphadenopathy	No	Clinical
Clinical suspicion on gynecomastia	On examination gynecomastia	No	Clinical
Age	Age	No	Clinical
Menopausal status	Menopausal state	No	Clinical
Painful retromamillary mass	Breast pain, breast mass	No	Clinical
Gynecomastia presentation (symmetric/asymmetric)	NA	No	Clinical
Pregnant	Pregnant	No	Clinical
BIRADS	NA	No	Radiology
Breast calcifications	Breast calcification	No	Radiology
cM status	Clinical M category	No	Radiology
cN status	Clinical N category	No	Radiology
cT status	Clinical T category	No	Radiology

(Continued on following page)

TABLE A1. All 114 Unique Data Items (Continued)

Data Item	SNOMED CT Description	Ambiguity in Data Item Present?	Data Source
cT diameter status	Tumor size	No	Radiology
Decrease left ventricular ejection fractions	Left ventricular ejection (qualifier value)	No	Radiology
Cortical thickness of ultrasonographic suspicious axillary lymph node	NA	No	Radiology
Distribution of calcifications	Diffuse nodular calcifications of breast	No	Radiology
Well-assessable mammography	Mammography assessment, needs additional imaging evaluation	Yes	Radiology
Clinical suspicion on distant metastases	NA	Yes	Radiology
Clinical suspicion on a phyllodes tumor	Phyllodes tumor of the breast	No	Radiology
Relapse location	Local recurrence of malignant tumor of breast	No	Radiology
Metastatic site(s)	Tumor metastatic to bone, cancer metastatic to liver	No	Radiology
Left ventricular ejection fraction	Left ventricular ejection fraction	No	Radiology
Occult breast mass	Occult carcinoma	No	Radiology
Response metastasis/metastases	Medication response	No	Radiology
Response primary tumor	Medication response	No	Radiology
rM	NA	No	Radiology
rN	NA	No	Radiology
Solid component on imaging	NA	No	Radiology
Solid mass in the breast	Breast mass	No	Radiology
Suspicious axillary lymph node on ultrasound imaging	Ultrasound of left axilla, ultrasound of right axilla, suspected lymphoma	No	Radiology
Symmetric cortex suspicious axillary lymph node on ultrasound imaging	NA	No	Radiology
Tumor distribution on mammography	NA	No	Radiology
Suspicious invasive component	Invasive tumor border	Yes	Radiology
DCIS with suspicious invasive component	NA	Yes	Radiology
ycN status	NA	No	Radiology
ycT status	NA	No	Radiology
ycT diameter status	NA	No	Radiology
Breast cytology result	Cytology	No	Pathology
Number of axillary sentinel lymph nodes with macrometastases	Axillary lymph nodes, number of lymph nodes with macrometastases, sentinel node	No	Pathology
Number of axillary sentinel lymph nodes with micro- and/or macrometastases	Axillary lymph nodes, number of lymph nodes with macrometastases, number of lymph nodes with micrometastases, sentinel node	No	Pathology
Number of axillary sentinel lymph nodes with micrometastases	Axillary lymph nodes, number of lymph nodes with micrometastases, sentinel node	No	Pathology
Number of sentinel lymph nodes with isolated tumor cells	Number of sentinel lymph nodes examined, tumor cell	No	Pathology
Number of sentinel lymph nodes with macrometastases	Number of lymph nodes with macrometastases	No	Pathology

(Continued on following page)

TABLE A1. All 114 Unique Data Items (Continued)

Data Item	SNOMED CT Description	Ambiguity in Data Item Present?	Data Source
Angioinvasion	Vascular invasion	No	Pathology
Previous incomplete surgical excision	Surgical margin finding	No	Pathology
Estrogen receptor status	Status of estrogen receptors of neoplasm	No	Pathology
Estrogen receptor status metastasis	Status of estrogen receptors of neoplasm, metastases status	No	Pathology
Estrogen receptor status recurrence	Status of estrogen receptors of neoplasm, recurrence of tumor	No	Pathology
Extranodal growth axillary lymph node dissection	Extracapsular extension of nodal tumor, axillary lymph node	No	Pathology
Extranodal growth sentinel node	Extracapsular extension of nodal tumor, sentinel node	No	Pathology
Extranodal growth axillary top lymph node	NA	No	Pathology
Gene mutation	Genetic mutation	No	Pathology
Tumor grade (postoperatively)	Tumor grade, postoperative diagnosis	No	Pathology
Tumor grade (preoperatively)	Tumor grade, preoperative diagnosis	No	Pathology
HER2 status	Human epidermal growth factor 2	No	Pathology
HER2 status (metastasis)	Human epidermal growth factor 2, metastases status	No	Pathology
HER2 status (postoperatively)	Human epidermal growth factor 2, postoperative diagnosis	No	Pathology
Lymphangitis cutis	Lymphangitis of breast	No	Pathology
Morphology	Morphology	No	Pathology
Morphology (postoperatively after neoadjuvant chemotherapy)	Morphology, postoperative diagnosis, neoadjuvant -intent	No	Pathology
Morphology (preoperatively after neoadjuvant chemotherapy)	Morphology, preoperative diagnosis, neoadjuvant-intent	No	Pathology
Morphology (preoperatively)	Morphology, preoperative diagnosis	No	Pathology
NO risk status	NA	No	Pathology
Pathologic tumor response	Pathologic staging	No	Pathology
pM status	Pathologic staging, metastases diagnosis	No	Pathology
pN status	Pathologic staging, cancer metastatic to lymph nodes	No	Pathology
Positive axillary lymph nodes	Neoplasm of axillary lymph nodes	No	Pathology
Positive infraclavicular lymph nodes	Neoplasm of infraclavicular lymph nodes	No	Pathology
Positive axillary top lymph node	NA	No	Pathology
Positive parasternal lymph nodes	Neoplasm of parasternal lymph nodes	No	Pathology
Positive parasternal lymph nodes sentinel node	Operation on sentinel lymph node, neoplasm of parasternal lymph nodes	No	Pathology
Positive supraclavicular lymph nodes	Neoplasm of supraclavicular lymph nodes	No	Pathology
Positive supraclavicular lymph nodes sentinel node	Operation on sentinel lymph node, neoplasm of supraclavicular lymph nodes	No	Pathology
pT	Pathologic staging	No	Pathology
pT diameter	Tumor size	No	Pathology
Surgical margin status	Surgical margin status	Yes	Pathology

(Continued on following page)

TABLE A1. All 114 Unique Data Items (Continued)

Data Item	SNOMED CT Description	Ambiguity in Data Item Present?	Data Source
Relapse surgical margin status	Surgical margins, local recurrence of malignant tumor	No	Pathology
Total number of axillary lymph nodes with macrometastases	Number of lymph nodes with macrometastases	No	Pathology
Total number of axillary lymph nodes with micro- and/or macrometastases	Number of lymph nodes with macrometastases, number of lymph nodes with micrometastases	No	Pathology
Total number of axillary lymph nodes with micrometastases	Number of lymph nodes with micrometastases	No	Pathology
Total number of lymph nodes with isolated tumor cells	Number of lymph nodes examined, tumor cells	No	Pathology
Residual tumor	Residual tumor	No	Pathology
Result cytology breast abnormality	Cytology diagnosis, breast tumor	No	Pathology
Result cytology lymph node	Cytology diagnosis, lymph node	No	Pathology
Result histology breast abnormality	Histology test, breast mass	No	Pathology
Result axillary lymph node dissection	Axillary lymph node dissection, pN	No	Pathology
Result sentinel node biopsy	Sentinel node biopsy	No	Pathology
Result sentinel node	Specimen from sentinel lymph node	No	Pathology
Result frozen section sentinel node	Frozen section lymph node sample	No	Pathology
Free surgical margin	Surgical margin(s) free of tumor	Yes	Pathology
ypN status	NA	No	Pathology
ypT status	NA	No	Pathology
ypT diameter status	NA	No	Pathology

NOTE. Data items are presented with the SNOMED CT description, if available; the qualification if a data item is ambiguous; and the source of data item origin (eg, MDT).

Abbreviations: BIRADS, Breast Imaging Reporting and Data System; DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; MDT, multidisciplinary team; NA, not available; SNOMED CT, Systematized Nomenclature of Medicine Clinical Terms.